Quest Diagnostics (DGX) Tops Q2 EPS by 2c; Maintains Guidance

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $1.25, $0.02 better than the analyst estimate of $1.23. Revenue for the quarter came in at $1.93 billion versus the consensus estimate of $1.93 billion.

Quest Diagnostics maintained FY2015 EPS of $4.70-$4.85, versus the consensus of $4.73.

"In the second quarter we once again grew operating income faster than revenues, demonstrating results from our five-point strategy. We are not just driving growth, we are driving profitable growth," said Steve Rusckowski, President and Chief Executive Officer. "Our strategies to restore growth and drive operational excellence are delivering both a better customer experience and earnings growth. An important element of restoring growth is to engage with healthcare systems around their lab strategy. Our recently announced acquisition of MemorialCare Health System's outreach business is another great example of this effort. Also, we have updated our outlook to reflect the clinical trials joint venture, and have maintained our full year EPS guidance."

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Palo Alto Networks (PANW) Tops Q3 EPS by 6c, Offers Guidance
• Macy's (M) Tops Q1 EPS by 10c, Beats on Revenue; Offers FY27 Guidance